secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2026-01-28T23:59:59+00:00
Accession:  0001171843-26-000462
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva posts FY 2025 revenue $17.3B (+4% YoY), non-GAAP EPS $2.93, guides FY26 rev $16.4-16.8B
--------------------------------------------------------------------------------

- FY 2025 revenues $17.3B (+4% YoY); GAAP diluted EPS $1.21, non-GAAP diluted EPS $2.93.
- Key innovative brands AUSTEDO ($2.26B, +34% YoY), AJOVY ($673M, +30%), UZEDY ($191M, +63%) drove 35% YoY growth.
- Non-GAAP operating income margin 28.4% (vs 26.2% in 2024); free cash flow $2,396M.
- Gross debt reduced to $16.8B, net debt to $13.3B; credit ratings upgraded by three agencies in 2025.
- 2026 outlook: revenues $16.4-16.8B, non-GAAP diluted EPS $2.57-2.77, free cash flow $2.0-2.4B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000117184326000462/0001171843-26-000462-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000117184326000462/f8k_012826.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-000462

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer